Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case–control study

References

• Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005;1753:11–22
   PubMed Web of Science ®Google Scholar
• Bellotti V, Nuvolone M, Giorgetti S, Obici L, Palladini G, Russo P, Lavatelli F, et al. The workings of the amyloid diseases. Ann Med 2007;39:200–7
   PubMed Web of Science ®Google Scholar
• Modesto KM, Dispenzieri A, Gertz M, Cauduro SA, Khandheria BK, Seward JB, Kyle R, et al. Vascular abnormalities in primary amyloidosis. Eur Heart J 2007;28:1019–24
   PubMed Web of Science ®Google Scholar
• Soutar AK, Hawkins PN, Vigushin DM, Tennent GA, Booth SE, Hutton T, Nguyen O, et al. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci U S A 1992;89:7389–93
   PubMed Web of Science ®Google Scholar
• Obici L, Franceschini G, Calabresi L, Giorgetti S, Stoppini M, Merlini G, Bellotti V. Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid 2006;13:191–205
   PubMed Web of Science ®Google Scholar
• Eriksson M, Schonland S, Yumlu S, Hegenbart U, von Hutten H, Gioeva Z, Lohse P, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn 2009;11:257–62
   PubMed Web of Science ®Google Scholar
• Hamidi AL, Liepnieks JJ, Hamidi AK, Uemichi T, Moulin G, Desjoyaux E, Loire R, et al. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1. Am J Pathol 1999;154:221–7
   PubMed Web of Science ®Google Scholar
• Gregorini G, Izzi C, Obici L, Tardanico R, Rocken C, Viola BF, Capistrano M, et al. Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol 2005;16:3680–6
   PubMed Web of Science ®Google Scholar
• Scalvini T, Martini PR, Obici L, Tardanico R, Biasi L, Gregorini G, Scolari F, et al. Infertility and hypergonadotropic hypogonadism as first evidence of hereditary apolipoprotein A-I amyloidosis. J Urol 2007;178:344–8
   PubMed Web of Science ®Google Scholar
• Scalvini T, Martini PR, Gambera A, Tardanico R, Biasi L, Scolari F, Gregorini G, et al. Spermatogenic and steroidogenic impairment of the testicle characterizes the hereditary leucine-75-proline apolipoprotein a-I amyloidosis. J Clin Endocrinol Metab 2008;93:1850–3
   PubMed Web of Science ®Google Scholar
• Obici L, Palladini G, Giorgetti S, Bellotti V, Gregorini G, Arbustini E, Verga L, et al. Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology 2004;126:1416–22
   PubMed Web of Science ®Google Scholar
• Booth DR, Tan SY, Booth SE, Hsuan JJ, Totty NF, Nguyen O, Hutton T, et al. A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM 1995;88:695–702
   PubMed Web of Science ®Google Scholar
• Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, Sirtori CR. A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest 1980;66:901–7
   PubMed Web of Science ®Google Scholar
• Rader DJ, Gregg RE, Meng MS, Schaefer JR, Zech LA, Benson MD, Brewer HB Jr. In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res 1992;33:755–63
   PubMed Web of Science ®Google Scholar
• Tilly-Kiesi M, Packard CJ, Kahri J, Ehnholm C, Shepherd J, Taskinen MR. In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107–>0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency. Atherosclerosis 1997;128:213–22
   PubMed Web of Science ®Google Scholar
• Gomaraschi M, Obici L, Simonelli S, Gregorini G, Negrinelli A, Merlini G, Franceschini G, et al. Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations. Clin Chim Acta 2011;412:1262–5
   PubMed Web of Science ®Google Scholar
• Marcel YL, Kiss RS. Structure-function relationships of apolipoprotein A-I: a flexible protein with dynamic lipid associations. Curr Opin Lipidol 2003;14:151–7
   PubMed Web of Science ®Google Scholar
• Mucchiano GI, Jonasson L, Haggqvist B, Einarsson E, Westermark P. Apolipoprotein A-I-derived amyloid in atherosclerosis. Its association with plasma levels of apolipoprotein A-I and cholesterol. Am J Clin Pathol 2001;115:298–303
   PubMed Web of Science ®Google Scholar
• Westermark P, Mucchiano G, Marthin T, Johnson KH, Sletten K. Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Am J Pathol 1995;147:1186–92
   PubMed Web of Science ®Google Scholar
• Alwitry A, Brackenbury ET, Beggs FD, Soomro I. Vascular amyloidosis causing spontaneous mediastinal haemorrhage with haemothorax. Eur J Cardiothorac Surg 2001;20:871–3
   PubMed Web of Science ®Google Scholar
• Genschel J, Haas R, Propsting MJ, Schmidt HH. Apolipoprotein A-I induced amyloidosis. FEBS Lett 1998;430:145–9
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, Salvetti M, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001;103:1949–54
   PubMed Web of Science ®Google Scholar
• Muiesan ML, Pasini G, Salvetti M, Calebich S, Zulli R, Castellano M, Rizzoni D, et al. Cardiac and vascular structural changes. Prevalence and relation to ambulatory blood pressure in a middle-aged general population in northern Italy: the Vobarno Study. Hypertension 1996;27:1046–52
   PubMed Web of Science ®Google Scholar
• Muiesan ML, Salvetti M, Zulli R, Pasini GF, Bettoni G, Monteduro C, Rizzoni D, et al. Structural association between the carotid artery and the left ventricle in a general population in Northern Italy: the Vobarno study. J Hypertens 1998;16:1805–12
   PubMed Web of Science ®Google Scholar
• Salvetti M, Muiesan ML, Rizzoni D, Bettoni G, Monteduro C, Corbellini C, Viola S, et al. Night time blood pressure and cardiovascular structure in a middle-aged general population in northern Italy: the Vobarno Study. J Hum Hypertens 2001;15:879–85
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308–47
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70
   PubMed Web of Science ®Google Scholar
• Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007;23:75–80
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Rosei EA, Dal PC, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998;16:1667–76
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, Parati G, et al. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation 2009;120:1084–90
   PubMed Web of Science ®Google Scholar
• Agabiti-Rosei E, Trimarco B, Muiesan ML, Reid J, Salvetti A, Tang R, Hennig M, et al. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2005;23:1091–8
   PubMed Web of Science ®Google Scholar
• Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, et al. [Practice guidelines 2007 for the treatment of arterial hypertension]. G Ital Cardiol (Rome) 2007;8:389–479
   PubMedGoogle Scholar
• Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588–605
   PubMed Web of Science ®Google Scholar
• Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De BT, Filipovsky J, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012;30:445–8
   PubMed Web of Science ®Google Scholar
• Gregorini G, Izzi C, Obici L, Tardanico R, Rocken C, Viola BF, Capistrano M, et al. Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol 2005;16:3680–6
   PubMed Web of Science ®Google Scholar
• Sorci-Thomas MG, Thomas MJ. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med 2002;12:121–8
   PubMed Web of Science ®Google Scholar
• de Sousa MM, Vital C, Ostler D, Fernandes R, Pouget-Abadie J, Carles D, Saraiva MJ. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol 2000;156:1911–17
   PubMed Web of Science ®Google Scholar
• Hovingh GK, Brownlie A, Bisoendial RJ, Dube MP, Levels JH, Petersen W, Dullaart RP, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 2004;44:1429–35
   PubMed Web of Science ®Google Scholar
• Rowczenio D, Dogan A, Theis JD, Vrana JA, Lachmann HJ, Wechalekar AD, Gilbertson JA, et al. Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol 2011;179:1978–87
   PubMed Web of Science ®Google Scholar
• Franceschini G, Sirtori CR, Capurso A, Weisgraber KH, Mahley RW. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980;66:892–900
   PubMed Web of Science ®Google Scholar
• Chiesa G, Monteggia E, Marchesi M, Lorenzon P, Laucello M, Lorusso V, Di MC, et al. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002;90:974–80
   PubMed Web of Science ®Google Scholar
• Bielicki JK, Oda MN. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 2002;41:2089–96
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 2005;45:1050–5
   PubMed Web of Science ®Google Scholar
• Pirro M, Schillaci G, Savarese G, Gemelli F, Vaudo G, Siepi D, Bagaglia F, et al. Low-grade systemic inflammation impairs arterial stiffness in newly diagnosed hypercholesterolaemia. Eur J Clin Invest 2004;34:335–41
   PubMed Web of Science ®Google Scholar
• Schillaci G, Pirro M. C-reactive protein in hypertension: clinical significance and predictive value. Nutr Metab Cardiovasc Dis 2006;16:500–8
   PubMed Web of Science ®Google Scholar
• Guerin AP, Pannier B, Metivier F, Marchais SJ, London GM. Assessment and significance of arterial stiffness in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2008;17:635–41
   PubMed Web of Science ®Google Scholar
• London GM, Marchais SJ, Guerin AP, Metivier F, Adda H, Pannier B. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int Suppl 2003;84:S88–93
   PubMedGoogle Scholar
• Yildiz M, Masatlioglu S, Seymen P, Aytac E, Sahin B, Seymen HO. The carotid-femoral (aortic) pulse wave velocity as a marker of arterial stiffness in familial Mediterranean fever. Can J Cardiol 2006;22:1127–31
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E. Familial Mediterranean fever (FMF) and renal AA amyloidosis–phenotype-genotype correlation, treatment and prognosis. J Nephrol 2003;16:431–4
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008;196:489–96
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Jr et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8–15
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707–14
   PubMed Web of Science ®Google Scholar
• Di AE, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993–2000
   PubMed Web of Science ®Google Scholar